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NEURONAL CELL MODEL AND METHODS 
OF USE THEREOF 
CROSS REFERENCE TO RELATED 
APPLICATION 
The present application claims the bene?t of priority to 
US. Provisional Application No. 60/243,701, ?led Oct. 27, 
2000. The contents of this provisional application are incor 
porated herein by reference in its entirety. 
FIELD OF THE INVENTION 
The present invention relates, in general, to neurally 
differentiated cells infected With viruses in a manner that 
supports a long-term non-productive infection for experi 
mentation concerning the reactivation, induction, suppress 
ing of virus latency. 
BACKGROUND OF THE INVENTION 
Herpes simpleX virus types 1 and 2 (HSV-1 and -2) are 
alphaherpesviruses With similar, but unique molecular (Kieff 
et. al., 1971, 1972), biological and clinical features 
(revieWed in Whitley, 1996). The genomes are approXi 
mately 150 kb in siZe and each contains corresponding sets 
of 74 genes (Dolan et al, 1998). Both viruses infect 
epithelium, With HSV-1 having a predilection for orofacial 
sites and HSV-2 preferentially infecting genital surfaces. 
During the primary infection, HSV invades local nerve 
endings and travels to sensory ganglia Where it can coloniZe 
neuronal nuclei and establish a latent state (Hill et al, 1972, 
Stevens and Cook, 1971). Reactivation of HSV from latency 
occurs intermittently as a result of stressful stimuli (e.g., 
trauma and heat). Reactivated viruses are responsible for 
causing recurrent epithelial infections that can occur in up to 
89% of infected individuals (Benedetti, et. al. 1994). 
The lack of a universally accepted neural cell culture 
model that supports HSV latency, in particular, HSV-2, 
restricts our understanding of the molecular events involved 
in reactivation from latency. Although animal models repro 
duce certain aspects of HSV-2 latency in humans (Al-Saadi 
et al, 1988; Bourne et al, 1994; Croen et al, 1991; Krause et 
al, 1995; Kurata et al, 1978; MacLean et al, 1991; Martin 
and Suzuki, 1989; Mitchell et al, 1990; Stanberry et al, 1982; 
Stephanopoulos et al, 1988; Wang et al, 1997; YoshikaWa et 
al, 1996), limitations in these models make interpretation of 
reactivation data challenging. Animal models limitations 
include: latency and reactivation events that are in?u 
enced by viral strains With different primary groWth 
phenotypes, (ii) the limited number of neurons latently 
infected in animal models (Bloom et al, 1996; Hill et al, 
1996; Maggioncalda et al, 1996; Mehta et al, 1995; 
Ramakrishnan 1994; SaWtell, 1997; SaWtell et al, 1998; 
Thompson and SaWtell, 1997), and (iii) inaccurate quanti 
tation of reactivation events When measuring virus produc 
tion at the recurrent site as a result of in?uences of transport, 
replication in epithelium, and the immune response. 
In response to these limitations, tissue and cell culture 
models of HSV-2 latency have been developed in an attempt 
to overcome limitations of animal models. A major advan 
tage of tissue and cell culture models includes the ability to 
observe virus at the single cell level Without the overlay of 
immunological events that modulate the eventual appear 
ance of virus in the host. In addition, tissue culture models 
derived from neuronal and sympathetic ganglia have prop 
erties of the in vivo system including: restricted tran 
scription of the HSV genome (Doerig et al, 1991; Halford et 
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al, 1996; Smith et al, 1992; Smith et al, 1994), (ii) lack of 
virus production folloWing removal of the inhibitory agent, 
(Wilcox and Johnson, 1988) (iii) the presence of latency 
associated transcripts (LATs) (Doerig et al, 1991; Smith et 
al, 1994), (iv) impaired reactivation of thymidine kinase 
negative virus (Wilcox et al, 1992), and (v) inducible 
reactivation (Halford et al, 1996; Moriya et al, 1994; Smith 
et al, 1992; WilcoX and Johnson, 1988; WilcoX and Johnson 
1987; WilcoX et al, 1990). Nevertheless, tissue culture 
models have their draWbacks, preparation of dissected gan 
glia is inconvenient, material is limited, animal use is 
required, and aXotomy introduces traumatic factors that 
in?uence reactivation of virus. 
Accordingly, development of cell culture models With 
neuronal characteristics that lack the restrictive require 
ments of tissue culture models Would be advantageous for 
understanding the molecular mechanisms of the 
establishment, maintenance and reactivation stages of HSV 
latency. Cell culture models also alloW for an unlimited 
supply of a de?ned host cell and the ability to manipulate 
genetic material. 
Over the past 25 years, cell culture systems using ?bro 
blast cultures (Harris and Preston, 1991; Jamieson et al, 
1995; O’Neill, 1977; O’Neill et al, 1972; Russell et al, 1987; 
Scheck et al, 1989; Wigdahl et al, 1982a; Wigdahl et al, 
1982b; Wigdahl et al, 1983) and lymphocytes (Hammer et 
al, 1981; Youssou?an et al, 1982) have enabled the study of 
HSV-1 during a latent-like state. These models, hoWever 
required loW input multiplicities and/or the use of replication 
inhibitors such as anti-viral agents, inhibitory temperatures, 
or the use of a mutant virus, to prevent virus production. A 
cell line that has neural morphology and physiology, can 
survive infection and permit viral production, alloW estab 
lishment of a long term nonproductive viral infection, and 
support virus in a state suitable for reactivation studies 
Would be more desirable. 
More recently, it has been reported that neurally 
differentiated PC12 (ND-PC12) cells can harbor HSV-1 in a 
quiescent, yet reversible state (Danaher et. al., 1999a). These 
quiescently infected ND-PC12 cultures (QIF-PC12) dem 
onstrate forskolin- and heat stress (HS)-inducible virus 
production in a high percentage (50—100%) of cultures for 
up to 8 Weeks after infection, Whereas mock-induced cul 
tures maintain the quiescent viral state in the majority of 
infected cultures (Danaher et al, 1999b). In contrast to these 
cell culture models, the present invention, hoWever, does not 
require antiviral conditions to maintain and/or establish the 
latent-like state (Colberg-Poley et al, 1979, 1981; Harris et 
al, 1989; Kondo et al, 1990; O’Neill, 1977; O’Neill et al, 
1972; Russell et al, 1987; Russell and Preston, 1986; 
Wigdahl et al, 1981; WilcoX and Johnson, 1988; WilcoX et 
al, 1990; Yura et al, 1986). 
The present application demonstrates that ND-PC12 cells 
permit establishment of an HSV-2 quiescent state, like 
HSV-1, folloWing transient acycloguanosine (ACV) treat 
ment. Unlike HSV-1, hoWever, antiviral conditions are not 
required for the establishment of the HSV-2 quiescent state. 
In addition, the present invention discloses quiescent cul 
tures in the presence of Vero cells, and the presence of Vero 
cells enhances the sensitivity to detect HSV-2 produced 
spontaneously and folloWing induction (i.e., forskolin and 
HS treatment). Thus, the present invention demonstrates that 
ND-PC 12 cells can harbor HSV-2, like HSV-1, in a cryptic 
and non-productive state that is reversible, and this model 
has appealing features for studying gene induction during 
the establishment and maintenance of virus latency and the 
activation of HSV-2 from a nonproductive state. 
US 6,573,041 B2 
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SUMMARY OF THE INVENTION 
Aprimary object of the present application is to provide 
neurally-differentiated cells infected With viruses in a man 
ner that supports a long-term non-productive infection for 
experimentation. Another object of the present invention 
also provides a cell culture research model for HSV-2 
quiescent infection in ND-PC12 cells to investigate quies 
cent and reactivation properties of HSV-2. This model 
represents an improvement over existing cell culture models 
for HSV-1. Advantages of this quiescently infected PC12 
cell culture model include: (1) establishment and mainte 
nance of a HSV-2 quiescent infection in a high proportion of 
PC12 cell cultures With and Without the transient use of ACV 
(acyclovir); (2) the ability to produce HSV-2 from a quies 
cent state in response to forskolin and HS treatment for at 
lest 4 Weeks post infection; and (3) the ability to discriminate 
betWeen quiescence, spontaneous reactivation and inducible 
reactivation using a range of multiplicities of infection 
(MOIs). Thereby, these enhanced features of the invention 
enable analysis of the establishment and maintenance of 
latency and the reactivation events of a cryptic HSV genome 
at the single neural cell level in vitro. 
Accordingly, additional objects of the present invention 
provide for methods of establishing quiescently-infected 
PC12 cells, reactivating quiescent virus, determining the 
ability of a test reagent to suppress and/or induce virus 
reactivation, eliciting phenotypic change in a PC12 cell, 
determining the susceptibility to reactivation of a person 
infected With a quiescent virus, identifying nucleic acid 
molecules and/or proteins involved in virus reactivation, 
identifying the origins of DNA replication important to virus 
reactivation, screening an altered virus’ ability to be 
reactivated, determining the ability of a non-neurotropic 
virus to become quiescent and/or reactivatable, and a 
method of determining a reagent’s ability to inhibit estab 
lishment of quiescent viral infection. 
Additional objects and attendant advantages of the present 
invention Will be set forth, in part, in the description that 
folloWs, or may be learned from practicing or using the 
present invention. The objects and advantages may be 
realiZed and attained by means of the instrumentalities and 
combinations particularly recited in the appended claims. It 
is to be understood that the foregoing general description 
and the folloWing detailed description are exemplary and 
explanatory only and are not to be vieWed as being restric 
tive of the invention, as claimed. 
The present invention provides, inter alia, neural cells 
comprising a PC12 cell quiescently infected With a neuro 
tropic virus. Preferred quiescently-infected neural cells are 
those Wherein the neurotropic virus is a neurotropic herpes 
virus. More preferred are quiescently-infected neural cells 
Wherein the neurotropic virus is a neurotropic human herpes 
virus. More preferred are quiescently-infected neural cells 
Wherein the neurotropic herpes virus is a human herpes 
simplex 2 virus. HoWever, those quiescently-infected neural 
cells Wherein the neurotropic virus is selected from the 
group consisting essentially of varicella Zoster viruses, 
polyoma viruses, measles viruses, human immunode?ciency 
viruses, papillomaviruses, adenoviruses, cytomegaloviruses, 
epstein barr viruses, hepatitis viruses, coronaviruses, cox 
sackie viruses, rabies viruses, ?aviviruses, paramyxoviruses, 
togaviruses, and rhinoviruses, are also preferred. 
Also provided are methods of establishing quiescently 
infected neural cells, comprising introducing a neurotropic 
virus to neurally-differentiated and viable PC12 cells in a 
serum-free medium, said differentiated PC12 cells being in 
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a container; and incubating said container With an antiviral 
reagent for a time necessary to accomplish quiescence of 
viral activity; and removing said antiviral agent from said 
container. Preferred such methods are those Wherein the 
neurotropic virus is a neurotropic herpes virus. More pre 
ferred are those methods Wherein the neurotropic herpes 
virus is a human herpes simplex 2 virus. HoWever, those 
methods Wherein the neurotropic virus is selected from the 
group consisting essentially of varicella Zoster viruses, 
polyoma viruses, measles viruses, human immunode?ciency 
viruses, papillomaviruses, adenoviruses, cytomegaloviruses, 
epstein barr viruses, hepatitis viruses, coronaviruses, cox 
sackie viruses, rabies viruses, ?aviviruses, paramyxoviruses, 
togaviruses, and rhinoviruses are also preferred. Methods 
Wherein the neurotropic herpes virus is a human herpes 
simplex 2 virus and the antiviral agent is acyclovir are 
preferred, especially those methods Wherein said container 
is incubated With an antiviral composition for approximately 
?ve (5) to tWelve (12) days, more especially methods 
Wherein said container is incubated at a temperature less 
than 40 degrees Celsius (40° C.), and most especially 
Wherein said serum free medium alloWs for constant cell 
density and imparts neural characteristics to said cells. 
Importantly, also provided are methods of establishing 
quiescently-infected neural cells Without using an antiviral 
reagent, comprising introducing a neurotropic virus to 
neurally-differentiated and viable PC12 cells in a serum-free 
medium; replenishing the serum-free medium after intro 
duction of the neurotropic virus to maintain acceptable cell 
viability. Preferably, the medium is replenished daily for 
three (3) days, and thereafter, every tWo (2) to three (3) days 
until experimentation. 
Also provided are methods of reactivating a quiescent 
virus from neural cell, comprising: introducing a reactivator 
to any of the herein described quiescently-infected neural 
cells. 
Also provided are methods for determining the ability of 
a test reagent to suppress virus reactivation from a 
quiescently-infected neural cell, comprising introducing a 
test reagent to a quiescently-infected neural cell described 
herein; and introducing to said neural cell a reactivator; and 
determining if reactivation has been suppressed. 
Also provided are methods for determining the ability of 
a test reagent to induce virus reactivation in a neural cell, 
comprising introducing a test reagent to a quiescently 
infected neural cell described herein; and determining if 
reactivation has been induced. 
Also provided are methods for determining the ability of 
a test reagent to establish virus latency in a neural cell, 
comprising introducing a test reagent to a quiescently 
infected neural cell described herein; and determining if 
latency has been induced. 
Also provided are methods for determining the ability of 
a test reagent to inhibit establishment of a quiescent viral 
infection, comprising introducing a virus to differentiated 
and viable PC12 cells; replenishing the serum-free medium 
after introduction of the non-neurotropic virus to maintain 
acceptable cell viability. Preferably, the medium is replen 
ished daily for three (3) days, and thereafter, every tWo (2) 
to three (3) days until experimentation. 
Also provided are methods for eliciting phenotypic 
change in a neural cell, introducing a reactivator to a 
quiescently-infected neural cell described herein, and elic 
iting a phenotypic change in said neural cell. Preferred are 
such methods Wherein said phenotypic change is selected 
from the group consisting of synthesis of myelin, synthesis 
of neurotransmitter, cell death, and viral shedding. 
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Also provided are methods for determining the suscepti 
bility of a person infected With a quiescent virus to reacti 
vation by a reagent, comprising introducing a reactivator to 
a quiescently-infected neural cell described herein, Wherein 
the neurotropic virus is a strain isolated from a person 
infected With said neurotropic virus; and determining the 
relative magnitude of phenotypic or genomic reactivation. 
Also provided are methods to identify nucleic acid mol 
ecules and/or proteins involved in virus reactivation, com 
prising reactivating a quiescently-infected neural cell 
described herein With a reactivator; and identifying nucleic 
acid molecules and/or proteins Which are uniquely expressed 
during reactivation. 
Also provided are methods to identify the origins of DNA 
replication important to virus reactivation, comprising reac 
tivating a quiescently-infected neural cell described herein 
With a reactivator; and identifying the origins of replication 
Which are uniquely associated With reactivation. 
Also provided are methods to identify nucleic acid mol 
ecules and/or proteins involved in establishing and main 
taining virus latency, comprising establishing latency of a 
neural cell described herein according to the methods 
described herein; and identifying nucleic acid molecules 
and/or proteins Which are uniquely expressed during latency. 
Also provided are methods to identify the origins of DNA 
replication important to establishing and maintaining virus 
latency, comprising establishing latency of a neural cell 
described herein according to the methods described herein; 
and identifying nucleic acid molecules and/or proteins 
Which are uniquely expressed during latency. 
Also provided are methods to screen an attenuated virus’ 
relative ability to be reactivated, comprising introducing a 
reactivator to a quiescently-infected neural cell described 
herein, Wherein the neurotropic virus is an attenuated virus; 
and determining the relative magnitude of reactivation. 
Also provided are methods to determine the ability of a 
virus to become quiescent and/or reactivatable in a neural 
cell line, comprising introducing a non-neurotropic virus to 
differentiated and viable PC12 cells in a serum-free medium; 
replenishing the serum-free medium after introduction of the 
neurotropic virus to maintain acceptable cell viability. 
Preferably, the medium is replenished daily for three (3) 
days, and thereafter, every tWo (2) to three (3) days until 
experimentation. 
DEFINITIONS 
For the purposes of the present application, the folloWing 
terms shall have the folloWing meanings: 
a or “an”, When describing a noun, refers to one or more 
of that noun. 
“acceptable cell viability” means suf?cient viability of 
quiescently infected cells to perform experiments. 
“antiviral reagent” means a reagent Which prevents viral 
groWth or DNA replication in a cell. 
“composition” means any compound or composition 
made by any means. “Composition” includes synthetic 
or naturally-occurring compounds or compositions, 
Whether puri?ed or not, and can include: biologicals, 
chemicals, herbal extract(s); precursor(s); metabolite 
(s); and ingredient(s), including enantiomer(s) of a 
racemic mixture. The de?nition of “composition” 
includes compounds produced in situ by virtue of an 
immune response (i.e., immunoglobulins and com 
pounds involved in in?ammation), as Well as 
organisms, such as: viruses, bacteria and fungi. 
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“isolated” means physically removed from a form found 
in nature. For instance, Whole cells, a crude cell extract, 
puri?ed virus, molecularly engineered virus, or arti? 
cial virus Would be “isolated” virus. 
“neurotropic virus” means any virus Which is capable of 
infecting neurons, including viruses Which only tran 
siently infect neurons. 
“quiescent” or “quiescence” means the absence of detect 
able infectious particles in the media and Within the 
cells having viral nucleic acid present in the cells. 
“reactivator” means a reagent Which Will cause reactiva 
tion of quiescent virus. 
“reactivation” means any change in phenotype or geno 
type from a quiescent state. 
“reagent” means a composition or an environmental 
condition, temperature, ultraviolet radiation, 
biological, etc. 
“virus” means the de?nition as understood by those in the 
art, as Well as viroid particles such as prions, and 
including natural and arti?cial alterations thereof (eg. 
mutations (eg. temperature sensitive mutations), 
including deletions, insertions, etc.) 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 shoWs induction of HSV-2 from QIF-PC12 cell 
cultures. Nonproductive cultures subjected to 50 pM for 
skolin (A), HS (43° C., 3 h) (I, or mock-induction (O) on 
day 15 pi. Parallel cultures cocultivated With Vero cells 2 
days after the forskolin induction ( Y 
FIGS. 2A and 2B shoW the effect of cocultivation on 
induction of HSV-1 from QIF-PC12 cell cultures. Nonpro 
ductive QIF cultures subjected to 50 pM forskolin (A), HS 
(43° C., 3 h) (I), or mock-induction (O) on day 15 pi. 
FIG. 3 shoWs that the reactivation of HSV-2 is multiplic 
ity of infection (MOI) dependent. Nonproductive cultures 
subjected to 50 pM forskolin (Y, MOI=3), (A, MOI=30), or 
mock-induction (O) on day 15 pi. 
FIG. 4 shoWs the reactivation of HSV-2 from QIF-PC12 
cell cultures established Without ACV. Nonproductive cul 
tures subjected to 50 pM forskolin (A) or mock-induction 
(O) on days 15 and 30 pi. 
DESCRIPTION OF THE INVENTION 
All patents, patent applications and literatures cited in this 
description are incorporated herein by reference in their 
entirety. In the case of inconsistencies, the present 
disclosure, including de?nitions, Will prevail. 
The mechanisms that govern HSV-2 reactivation from 
latency remain unknoWn. An obstacle to understanding 
HSV-2 latency and reactivation has been the lack of in vitro 
models that permit analysis of HSV-2 quiescence and induc 
tion at the neuronal and clonal cell level. In a preferred 
embodiment, the present invention is neurally-differentiated 
cells infected With viruses in a manner that supports a 
long-term nonproductive infection for experimentation. 
Also in a preferred embodiment, the invention is directed to 
a cell culture research model for HSV-2 quiescent infection 
in ND-PC12 cells to investigate quiescent and reactivation 
properties of HSV-2. This model represents an improvement 
of existing cell culture models for HSV-1. Advantages of the 
QIF-PC12 cell culture model include: (1) establishment and 
maintenance of a HSV-2 quiescent infection in a high 
proportion of PC12 cell cultures With and Without the 
transient use of ACV; (2) the ability to produce HSV-2 from 
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a quiescent state in response to forskolin and HS treatment 
for as long as 4 Weeks post infection; and (3) the ability to 
discriminate betWeen quiescence, spontaneous reactivation 
and inducible reactivation using a range of MOIs. Thereby 
these enhanced features of the invention enable the analysis 
of reactivation events of a cryptic HSV genome at the single 
neural cell level in vitro. 
The present invention provides, inter alia, neural cells 
comprising a PC12 cell quiescently infected With a neuro 
tropic virus. Preferred quiescently-infected neural cells are 
those Wherein the neurotropic virus is a neurotropic herpes 
virus. More preferred are quiescently-infected neural cells 
Wherein the neurotropic virus is a neurotropic human herpes 
virus. More preferred are quiescently-infected neural cells 
Wherein the neurotropic herpes virus is a human herpes 
simplex 2 virus. HoWever, those quiescently-infected neural 
cells Wherein the neurotropic virus is selected from the 
group consisting essentially of varicella Zoster viruses, 
polyoma viruses, measles viruses, human immunode?ciency 
viruses, papillomaviruses, adenoviruses, cytomegaloviruses, 
epstein barr viruses, hepatitis viruses, coronaviruses, cox 
sackie viruses, rabies viruses, ?aviviruses, paramyxoviruses, 
togaviruses, and rhinoviruses, are also preferred. 
Certain PC12 cells are available commercially as 
described in the examples. PC12 cell variants are Within the 
scope of the present invention, as are any cells derived from 
the neural crest. These materials can be commercially 
obtained from American Type Culture Collection (ATCC, 
Rockville, Md.) or other commercial entities. These cells are 
Within the scope of the present invention as Well. There are 
eight (8) types of herpes virus. For instance, human herpes 
virus 1, human herpes virus 2, human herpes virus 6, human 
herpes virus 7, and human herpes viruses 8 are “types” of 
human herpes virus. Within the meaning of each of the 
viruses listed in the claims are several hundreds of “strains” 
of those viruses. The strains of each virus type are, of course, 
included Within the scope of the present invention. For 
instance, human HSV-2 includes the strains listed in the 
examples, as Well as these other strains, such as G and 333 
HSV-2 strains. 
Viruses can be obtained by purchasing them commer 
cially (as part of a cell line or tissue sample) from ATCC or 
by obtaining them according to the procedures Well knoWn 
in the art, such as by obtaining clinical isolates, or cultures 
from researchers in the ?eld. Textbooks Which discuss 
manipulations of viruses are many, including: Fields & 
Knipe, Fundamental Virology; Luria et al, General Virology; 
and Fenner et al., Molecular Virology. The present 
quiescently-infected neural cells can be made by the meth 
ods disclosed herein. 
Particularly useful in the preparation of the neural cells 
are the examples, although variations as described herein 
Will also produce the present materials. Moreover, certain 
reasonable optimiZation of the methods can be accomplished 
according to methods Well-known in the art. 
In addition, a signi?cant aspect of this invention provides 
the methods of establishing quiescently-infected neural 
cells. One such method comprises introducing a neurotropic 
virus to neurally-differentiated and viable PC12 cells in a 
serum-free medium, said differentiated PC12 cells being in 
a container; and incubating said container With an antiviral 
reagent for a time necessary to accomplish quiescence of 
viral activity; and removing said antiviral agent from said 
container. Preferred methods comprise human herpes sim 
plex 2 virus as the neurotropic herpes virus and acyclovir as 
the antiviral agent, especially Wherein said container is 
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incubated With an antiviral composition for approximately 
?ve (5) to tWelve (12) days, more especially Wherein said 
container is incubated at a temperature less than 40 degrees 
Celsius (40° C.), and most especially Wherein said serum 
free medium alloWs for constant cell density and imparts 
neural characteristics to said cells. HoWever, those methods 
Which also include a neurotropic virus selected from the 
group consisting essentially of varicella Zoster viruses, 
polyoma viruses, measles viruses, human immunode?ciency 
viruses, papillomaviruses, adenoviruses, cytomegaloviruses, 
epstein barr viruses, hepatitis viruses, coronaviruses, cox 
sackie viruses, rabies viruses, ?aviviruses, paramyxoviruses, 
togaviruses, and rhinoviruses are also preferred. 
Another such method of establishing quiescently-infected 
neural cells comprises introducing neurotropic virus to 
neurally-differentiated and viable PC12 cells in a serum-free 
medium, and replacing the serum-free culture medium With 
fresh serum-free media to maintain acceptable neurally 
differentiated cell’s viability. Preferably the culture media is 
replenished daily for three (3) days after introduction of the 
neurotropic virus to the neurally-differentiated PC12 cells, 
and thereafter, every tWo (2) to three (3) days until experi 
mentation. Further preferred methods are those Wherein the 
neurotropic virus is a neurotropic herpes virus and still more 
preferred are those methods Wherein the neurotropic herpes 
virus is a human herpes simplex 2 virus. HoWever, those 
methods Which also include a neurotropic virus selected 
from the group consisting essentially of varicella Zoster 
viruses, polyoma viruses, measles viruses, human immuno 
de?ciency viruses, papillomaviruses, adenoviruses, 
cytomegaloviruses, epstein barr viruses, hepatitis viruses, 
coronaviruses, coxsackie viruses, rabies viruses, 
?aviviruses, paramyxoviruses, togaviruses, and rhinoviruses 
are also preferred. 
The methods described herein may utiliZe the speci?c 
conditions described in the examples, but may also vary 
therefrom. Variations include the use of collagen in the 
plating technique; collagen need not be used, but ef?ciency 
Will be improved if it is. Moreover, the plates need not be as 
con?ning as described in the examples; other surfaces, 
including different shapes and siZes, can be used, so long as 
a viable cell culture can be maintained for the length of time 
desired. The multiplicity of infection may be from 0.5 to 
greater than 15, although the examples describe preferred 
higher multiplicities for HSV-2 When high reactivation rates 
are desired. HoWever, in certain instances, it may be optimal 
to have loW reactivation rates, depending on the particular 
use of the neural cells. In that case, loWer multiplicities 
Would be optimal. The antiviral reagent used can be any 
Which causes quiescence of the neurotropic virus. The 
exempli?ed reagent, acycloguanosine, may be optimiZed 
chemically for this purpose, or other antivirals may be used. 
For example, Zidovudine (AZT), lamivudine (3TC) indi 
navir (IDV), ganciclovir, famiciclovir, foscarnet, 
idoxyuridine, phosphoacetic acid, 5-?uorouracil, or similar 
compounds and analogs thereof may be used. The concen 
trations of the compound used to cause quiescence can also 
be modi?ed as necessary. Moreover, a combination (eg. tWo 
or more) of antiviral drugs may be used. Incubation of the 
PC12 cells With the antiviral is optimally that described in 
the examples, but can be more or less, depending on the 
particular reagent used. OptimiZation of the incubation 
schedule is Within the skill of the art. Lastly, the media used 
can be any that alloWs viable cell groWth, so long as it alloWs 
for constant cell density and may be supplemented reagent 
or virus in order to transiently inhibit viral groWth. It is 
optimal to change the media as described in the examples, 
but it is not necessary, so long as the cells are acceptably 
viable. 
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Also provided are methods of reactivating a quiescent 
virus from neural cell, comprising: introducing a reactivator 
to a quiescently-infected neural cell described herein. This 
aspect of the invention is particularly useful in studying 
reactivation, as Well as in studying quiescence. The infor 
mation gleaned from reactivation and quiescence studies 
Will be of bene?t in drug discovery. The preferred 
quiescently-infected neural cells for use in this embodiment 
are those comprising neurotropic herpes viruses, preferably 
HSV-Z. The neural cells can be prepared as described herein 
and introducing a reactivator can be accomplished according 
by any means Which causes reactivation. 
Also provided are methods for determining the ability of 
a test reagent to suppress virus reactivation from a 
quiescently-infected neural cell, comprising, introducing a 
test reagent to a quiescently-infected neural cell described 
herein; and introducing to said neural cell a reactivator; and 
determining if reactivation has been suppressed. This aspect 
of the invention is particularly useful for identifying poten 
tial anti-viral drugs. The preferred quiescently-infected neu 
ral cells for use in this embodiment are those comprising 
neurotropic herpes viruses, preferably HSV-Z. The neural 
cells can be prepared as described herein; introducing a 
reactivator can be accomplished by any means Which causes 
reactivation; and determining reactivation can be accom 
plished by any means, including, for example, those means 
described in the examples, or other Well-known means. 
Also provided are methods for determining the ability of 
a test reagent to induce virus reactivation from a neural cell, 
comprising introducing a test reagent to a quiescently 
infected neural cell described herein; and determining if 
reactivation has been induced. This aspect of the invention 
is particularly useful for identifying potential reactivators. In 
one aspect, this embodiment is useful in drug discovery as 
part of a toxicology screen. For example, if a reagent such 
as a drug (or potential drug), vaccine, carrier, food, or 
environmental condition is implicated through the use of this 
method as a reactivator of quiescent virus, it Would be 
advisable for an infected individual to avoid the reagent, 
since reactivation of virus is normally detrimental to the 
individual. The preferred quiescently-infected neural cells 
for use in this embodiment are those comprising neurotropic 
herpes viruses, preferably HSV-Z. The neural cells can be 
prepared as described herein; introducing a test compound 
can be accomplished by any means Which causes interaction 
betWeen the test compound and the neural cells; and deter 
mining reactivation can be accomplished by any means, 
including, for example, those means described in the 
examples, or other Well-known means. 
Also provided are methods to determine a reagent’s 
ability to inhibit establishment of a viral infection, compris 
ing introducing a virus to differentiated and viable PC12 
cells in a serum-free, test reagent-containing medium, said 
differentiated PC12 cells being in a container; and incubat 
ing said container With an antiviral reagent for a time 
necessary to accomplish quiescence of viral activity in the 
absence of said test reagent; and removing said antiviral 
agent from said container; and determining said test 
reagent’s ability to inhibit quiescence. This aspect of the 
invention is particularly useful for identifying reagents 
Which could be used as an anti-viral drug. The reagents 
identi?ed as inhibiting the establishment of quiescence 
Would be particularly effective to administer during the ?rst 
lytic phase of a viral infection. Additionally, methods to 
determine a reagent’s ability to inhibit establishment of a 
viral infection, comprise introducing a virus to differentiated 
and viable PC12 cells in a serum-free, test reagent 
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containing medium, replacing the serum-free medium With 
fresh serum-free, test reagent-containing medium after intro 
duction of the non-neurotropic virus to the differentiated 
PC12 cells to maintain acceptable differentiated PC12 cell 
viability. Preferably, the media is replenished daily for three 
(3), and thereafter, every tWo (2) to three (3) days. The 
preferred neural cells for use in this embodiment are those 
Which are neurotropic herpes viruses, speci?cally HSV-2. 
Also provided are methods for eliciting phenotypic 
change in a neural cell, introducing a reactivator to a 
quiescently-infected neural cell described herein, and elic 
iting a phenotypic change in said neural cell. Preferred are 
such methods Wherein said phenotypic change is selected 
from the group consisting of synthesis of myelin, synthesis 
of neurotransmitter, degradation of neurotransmitters, cell 
death, and viral shedding. This aspect of the invention is 
particularly useful in studying disease states, such as mul 
tiple sclerosis, or other neuron-associated diseases. The 
neural cells can be directed via molecular techniques, for 
example, to result in disease state upon activation. 
Alternatively, the neural cells can be directed to be positive 
in?uences on the environment, such that gene therapy stud 
ies Will be possible using this embodiment. In all aspects of 
the present embodiment, the methods Will be useful for drug 
discovery in that the mechanisms of phenotypic change can 
be studied. The preferred quiescently-infected neural cells 
for use in this embodiment are those comprising neurotropic 
herpes viruses, preferably HSV-Z. 
Also provided are methods for determining the suscepti 
bility of a person infected With a quiescent virus to reacti 
vation by a reagent, comprising introducing a reactivator to 
a quiescently-infected neural cell described herein, Wherein 
the neurotropic virus is a strain isolated from a person 
infected With said neurotropic virus; and determining the 
relative magnitude of phenotypic or genomic reactivation. 
This aspect of the present invention is particularly useful for 
patient diagnosis and directed medical care. Since some 
strains are more reactivatable than others are, it is important 
to determine the aggressiveness and/or timing of treatment. 
The present embodiment, for example, can identify those 
individuals Who harbor a strain particularly reactivatable by 
sunlight, in Which those patients could use sunscreen or 
avoid the sun. The method Would provide information to 
patients Who have a less reactivatable strain, so that sup 
pressor drug levels can be loWered in comparison to those 
Who have a highly reactivatable strain. The preferred 
quiescently-infected neural cells for use in this embodiment 
are those comprising neurotropic herpes viruses, preferably 
HSV-2. 
Also provided are methods to determine the ability of a 
non-neurotropic virus to become quiescent and/or reactivat 
able in a neural cell line, comprising introducing a non 
neurotropic virus to differentiated and viable PC12 cells in 
a serum-free medium, said differentiated PC12 cells being in 
a container; and incubating said container With an antiviral 
reagent for a time necessary to accomplish quiescence of 
viral activity; and removing said antiviral agent from said 
container; and determining said non-neurotropic virus’s 
ability to become quiescent and or reactivatable. In addition, 
methods are provided to determine the ability of a non 
neurotropic virus to become quiescent and/or reactivatable 
in a neural cell line, comprising introducing a non 
neurotropic virus to differentiated and viable PC12 cells in 
a serum-free medium, said serum-free medium being replen 
ished With fresh serum-free media to maintain acceptable 
differentiated PC12 cell viability. Preferably the media is 
changed daily for the ?rst three (3) days after introduction of 
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the non-neurotropic virus, and thereafter every tWo (2) to 
three (3) days. This aspect of the present invention is 
particularly useful to identify additional viruses Which may 
be amenable to the present invention. The preferred 
quiescently-infected neural cells for use in this embodiment 
are those comprising neurotropic herpes viruses, preferably 
HSV-2. 
Also provided are methods to identify nucleic acid mol 
ecules and/or proteins involved in virus reactivation, com 
prising reactivating a quiescently-infected neural cell 
described herein With a reactivator; and identifying nucleic 
acid molecules and/or proteins Which are uniquely expressed 
during reactivation. This aspect of the present invention is 
particularly useful for general scienti?c research or to study 
possible targets for drug discovery. The preferred 
quiescently-infected neural cells for use in this embodiment 
are those comprising neurotropic herpes viruses, preferably 
HSV-2. 
Also provided are methods to identify the origins of DNA 
replication important to virus reactivation, comprising reac 
tivating a quiescently-infected neural cell described herein 
With a reactivator; and identifying the origins of replication 
Which are uniquely associated With reactivation. This aspect 
of the present invention is particularly useful for general 
scienti?c research or to study possible targets for drug 
discovery. The preferred quiescently-infected neural cells 
for use in this embodiment are those comprising neurotropic 
herpes viruses, preferably HSV-2. 
Also provided are methods to screen an attenuated virus’ 
relative ability to be reactivated, comprising introducing a 
reactivator to a quiescently-infected neural cell described 
herein, Wherein the neurotropic virus is an attenuated virus; 
and determining the relative magnitude of reactivation. This 
aspect of the invention is particularly useful to determine the 
reactivatability of potential or actual vaccines. Vaccines 
Which can reactivate, Whether alone, or in combination With 
an additional reagent, Would be potentially dangerous. In 
other Words, this aspect of the invention can be used a 
specially-designed toxicology assay. The preferred 
quiescently-infected neural cells for use in this embodiment 
are those comprising neurotropic herpes viruses, preferably 
HSV-2. 
EXAMPLE 1 
Virus and Cells 
Rat pheochromocytoma (PC12) and Vero (Africa green 
monkey kidney) cells Were obtained from ATCC (Rockville, 
Md., USA). All culture media and supplements Were pur 
chased from Gibco BRL (Gaithersburg, Md., USA) unless 
otherWise indicated. PC12 cells Were groWn in RPMI 1640 
media containing 5% fetal bovine serum (FBS) and 10% 
heat-inactivated horse serum. Vero cells Were groWn and 
maintained in M199 medium containing 5% FBS. Cells 
Were incubated at 37° C. in humidi?ed incubator With 5% 
CO2. All media Was supplemented With penicillin (100 
units/ml) an (streptomycin (100 pig/ml). HSV-2 strain 333 
Was a kind gift from Philip R Krause (Food and Drug 
Administration, Bethesda, Md., USA). Viral stocks Were 
prepared in Vero cells and maintained at —85° C. 
In particular, the neuronally-differentiated PC12 cells 
Were established from pheochromocytoma of rat adrenal 
medulla, and used to host a persistent viral infection. Neural 
differentiation of the PC12 cells comprises groWing cells in 
de?ned medium containing nerve groWth factor. Under these 
conditions cells extend neurites, develop electrical excitabil 
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ity and express genes encoding neuronal cell-speci?c pro 
teins (Green and Tischler 1976; Green and Tischler 1982). 
Cells are maintained in serum-free medium to render them 
non-dividing. Next, cells are inoculated With neurotropic 
virus (eg., human herpes virus) under conditions that restrict 
viral propagation. A de?ned regimen of media changes is 
used to establish a quiescent and nonproductive state fol 
loWing the WithdraWal of the antiviral treatment. Evidence 
of establishment of a quiescent and persistent infection 
comes from assays demonstrating that cells survive the 
infection, a nonproductive viral state is established in the 
majority of cultures, and cells support spontaneous and 
inducible virus production. 
EXAMPLE 2 
Morphologic Differentiation 
For morphologic differentiation, PC12 cells Were main 
tained in RPMI 1640 supplemented 0.1% bovine serum 
albumin, fraction V (BSA) and 50 ng/ml of 2.5S mouse 
nerve groWth nerve factor (NGF) (Becton Dickinson) 
(maintenance media) throughout the studies, unless 
indicated, beginning on the day of plating. PC12 Were 
plated, folloWing tWo rinses With RPMI 1640 containing 
0.1% BSA and dissociation by passage through a 22-gauge 
needle, in 12-Well tissue culture dishes (Bector Dickinson 
LabWare, Franklin Lakes, N.J., USA) coated With rat tail 
collagen type 1 (Bector Dickinson) at 1.1><105 cells/Well in 
maintenance media. Collagen Was applied as recommended 
by the supplier. FolloWing 4 days of differentiation in 
maintenance media, cultures Were maintained in RPMI 1640 
supplemented With 10% horse serum (heat-inactivated) and 
5% FBS, and 50 ng/ml NGF for 2 days. The folloWing day 
cultures received maintenance media supplemented With 
100 pM acycloguanosine (ACV) When indicated, purchased 
from Sigma (St. Louis, Mo., USA). Morphologic differen 
tiation Was con?rmed by microscopic visualiZation of den 
dritic processes. Media Was changed every 2 to 3 days unless 
indicated. 
EXAMPLE 3 
Establishment of a Quiescent Infection 
ND-PC12 cells Were infected in a volume of 0.4 ml/Well 
in 12-Well plates Without agitation at the indicated multi 
plicity of infection (MOI) overnight at 37° C. When used, 
ACV Was maintained in the medium from 1 day prior to 
infection 8 days post-infection After ACV WithdraWal, 
a quiescent state (i.e., free of detectable infectious virus in 
culture supernatants) Was maintained for at least 7 days prior 
to induction. At the indicated times, Vero cells Were 
trypsiniZed, Washed tWice With RPMI and introduced into 
the QIF-PC12 cell cultures at a ratio of 1:1 in maintenance 
media. 
EXAMPLE 4 
Induction Stimuli and Assay of Virus Production 
HSV QIF-PC12 cells, that Were free of detectable infec 
tious virus, Were subjected to heat stress (43° C. for 3 h in 
an incubator), or maintenance media supplemented With or 
Without 50 pM forskolin (Sigma) as previously described 
(Danaher et al, 1999a,b). Virus production Was determined 
using 25% volume of supernatants from infected PC12 
cultures in a direct plaque assay (DPA) on monolayers of 
Vero cells as previously described (Miller and Smith, 1991). 
Cultures Were subsequently replenished With fresh mainte 
nance media. 
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EXAMPLE 5 
HSV-2 Establishes a Quiescent Infection in ND 
PC12 Cells That is Reversible. 
Preliminary data indicated that QIF-PC12 cell cultures 
established With HSV-2 produce virus following heat stress 
and forskolin and forskolin induction (data not shoWn). 
HoWever, unlike previous ?ndings With HSV-1, minimal 
amounts of virus (i.e., only a single plaque forming unit) 
Were detected in the majority of QIF-PC12 cell cultures 
determined to be positive for HSV-2 production folloWing 
induction. Furthermore, cocultivation of HSV-2 established 
QIF-PC12 cell cultures With Vero cells did not increase the 
proportion of cultures producing virus, but increased the 
amount of virus detected from such cultures. This indicated 
that HSV-2 Was not induced from QIF-PC-12 cell cultures 
by cocultivation With Vero cells, and Vero cells could be 
used to increase the sensitivity of the system. 
Based on these ?ndings, forskolin and HS induced HSV-2 
reactivation from QIF-PC12 cell cultures that Were coculti 
vated With Vero cells Was analyZed in more detail. QIF 
PC12 cell cultures Were established With strain 333 at MOI 
of 10 as described in the Materials and methods using 
transient ACV treatment. Cultures Were cocultivated With 
Vero cells at a ratio of 1:1 three days before induction With 
forskolin or HS (day 15 p.i.). Virus production Was moni 
tored from day 10 through 23 pi. Prior to induction, HSV-2 
Was detected infrequently (2.8%; 1/36) in cocultivated cul 
tures. The 35 cultures that Were not shedding virus Were used 
in induction assays. FolloWing induction treatment (FIG. 1), 
virus Was detected in 90 to 100% of HS and forskolin 
induced cocultivated cultures, and 8.3% (1/12) of mock 
induced cocultivated cultures. These data indicate that qui 
escently infected cultures can be established With HSV-2 and 
virus production can be induced by both physical and 
chemical stimuli. 
The possibility that Vero cells in?uenced HSV induction 
from QIF-PC12 cell cultures Was assessed in tWo Ways. 
First, parallel neuronal cultures established With HSV-2 
Were cocultivated With Vero cells 2 days after induction With 
forskolin. This alloWed for comparison of virus production 
occurring before and after cocultivation. Second, induction 
of HSV-1 established cultures Was analyZed in the presence 
and absence of Vero cell cocultivation, as detection of 
HSV-1 progeny from such cultures does not require Vero 
cells (Danaher et al, 1999a). QIF-PC12 cell cultures Were 
established With HSV-2 strain 333 at MOT of 10 With the 
transient use of ACV as described in the Material and 
methods. Cultures Were cocultivated With Vero cells at a 1:1 
ratio 3 days before induction. Nonproductive cultures Were 
subjected to 50 pM forskolin, HS (43° C., 3 h), or mock 
induction on day 15 pi. Cultures Were monitored for virus 
production using culture supernatants in the direct plaque 
assay. Virus Was detected in 2.8%; (1/36) of cultures coc 
ultivated before induction and 0% (0/12) of cultures cocul 
tivated after induction betWeen day of ACV WithdraWal (day 
8 pi.) and day of induction. In HSV-2 established cultures 
(FIG. 1), virus Was detected in a similar proportion of 
cultures by day 4 post-forskolin treatment Whether cultures 
Were cocultivated before or after induction. 
This indicated that the Vero cells did not contribute to 
induction of HSV-2, but merely alloWed for detection of 
progeny virus. Results shoWn in FIG. 2 demonstrate that 
cocultivation of HSV-1 established QIF-PC12 cell cultures 
With Vero cells did not induce HSV-1 production or alter the 
ef?ciency of the response to forskolin and HS. QIF-PC 12 
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cell cultures Were established With HSV-1 strain 17+ at MOI 
of 1 With the transient use of ACV as described in the 
Material and methods. Cultures Were either mock coculti 
vated (A), or cocultivated With Vero cells at a 1:1 ratio 3 
days before induction Nonproductive QIF cultures Were 
subjected to 50 pM forskolin, HS (43° C., 3 h), or mock 
induction on day 15 pi. Cultures Were monitored for virus 
production using culture supernatants in the direct plaque 
assay. Virus Was detected in 0% (0/72) mock cocultivated 
and 1.7% (1/60) Vero cocultivated cultures betWeen the day 
of ACV WithdraWal (day 8 pi.) and day of induction. 
Therefore, the ?ndings from these tWo experiments dem 
onstrate that cocultivation With Vero cells did not contribute 
to the reactivation response. Furthermore, HSV-1 and -2 
established QIF-PC12 cell cultures can maintain a non 
productive state in the presence of Vero cells. This indicates 
that loW amounts of infectious virus are not being chroni 
cally shed and the cultures are truly quiescent. 
EXAMPLE 6 
Long-Term HSV-2 Quiescent Infection in PC12 
Cells Cocultivated With Vero Cells 
The ability of HSV-2 to maintain a short-term quiescent 
infection in ND-PC12 cells suggested such a state could be 
maintained long-term in the presence of Vero cell coculti 
vation. To assess this, QIF-PC12 cell cultures Were estab 
lished With HSV-2 as described above. Cultures Were coc 
ultivated With Vero cells at a ratio of 1:1 Within 10 days of 
AC WithdraWal. Induction Was performed With forskolin on 
day 30 pi. Cultures Were monitored for virus production 
using culture supernatants. Over the 3 Week period betWeen 
ACV WithdraWal and induction, 71% (17/24) of the HSV-2 
infected culture maintained quiescence. HSV-2 Was pro 
duced from 100% (8/8) of forskolin induced cultures and 0% 
(0/9) of mock induced cultures by 8 days post-induction 
(data not shoWn). These data indicate that long-term HSV 
quiescence can be maintained in QIF-PC12 cell cultures in 
the presence of Vero cell cocultivation and absence of ACV, 
and these cultures reactivate virus When induced With for 
skolin 30 days p.i. 
EXAMPLE 7 
Reactivation of HSV-2 is MOI Dependent 
Next, it Was determined Whether the ef?ciency of HSV-2 
activation from quiescence Was MOI-dependent. QIF-PC12 
cell cultures Were established With HSV-2 strain 333 at 
MOIs of 3 and 30 and cocultivated With Vero cells at a ratio 
of 1:1 on day 12 pi. as above. Nonproductive cultures 
harboring a quiescent infection on day 15 pi. Were subjected 
to forskolin (50 pM) or mock induction. Virus production 
Was monitored using cultured supernatants as described 
above. BetWeen the period of ACV WithdraWal and 
induction, virus Was detected in 4.2% (1/24) of cultures for 
each MOI. FIG. 3 shoWs that viral MOI in?uenced the 
ef?ciency of HSV-2 activation from quiescence. Cultures 
infected at MOI of 30 activated virus at a higher rate (i.e., 
1—2 days faster) and degree (100%; 12/12 by day 6) in 
response to forskolin, than cultures infected at MOI of 3 
(82%; 9/11 by day 7). 
In the mock-induced QIF-PC12 control cultures, sponta 
neous virus production Was not detected (0%; 0/11, 0/12) at 
either MOI. These data indicate that the ef?ciency of for 
skolin induced HSV-2 activation from QIF-PC12 cell cul 
tures is MOI-dependent. Moreover, QIF-PC12 cell cultures 
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established With ACV at higher MOI yielded HSV-2 sooner 
and from a higher proportion of cultures following induction 
than those established at a loWer MOI. A majority of these 
cultures maintained HSV-2 in a quiescent state for at least 30 
days and virus Was inducible thereafter With forskolin. 
EXAMPLE 8 
ACV is Not Required for the Establishment of a 
Quiescent Infection With HSV-2 
Since HSV-2 Was found to be non-permissive in ND-PC 
12 cells (data not shoWn), We assessed the ability of HSV-2 
to establish a quiescent infection Without the use of ACV. 
QIF-PC12 cell cultures Were established With HSV-2 strain 
333 in the absence of ACV in parallel to the above experi 
ment. Cultures Were cocultivated With Vera cells at a ratio of 
1:1 on day 12 pi. Nonproductive cultures Were subjected to 
50 nM forskolin or mock-induction on days 15 and 30 pi. 
Cultures Were monitored for virus production by direct 
plaque assay of supernatants. Virus Was detected in 3/24 
(12%) of cultures betWeen day 8 pi. and day of initial 
induction. Following infection, the culture media Was 
changed daily for 3 days pi. and thereafter every 2 to 3 days 
until induction. 
The majority of cultures maintained quiescence at MCI of 
3 (88%, 21/24) and 30 (79%, 19/24) until the day of 
induction (day 15 pi.) FIG. 4 shoWs that HSV-2 Was 
produced from 91% (10/11) of forskolin induced and 10% 
(1/ 10) of mock induced cultures established at MCI of 3 by 
day 6 post-induction. Parallel cultures established at MCI of 
30 demonstrated a similar level of forskolin induced reac 
tivation (90%, 9/ 10) and slightly higher (22%, 2/9) sponta 
neous virus production than cultures established at MOI of 
3 (data not shoWn). In addition, the mock induced MOI of 
3 cultures that Were non-productive on day 23 Were main 
tained for an additional 7 days, and on day 30 pi. Were mock 
or forskolin induced. Virus Was recovered from 100% (4/4) 
of forskolin induced cultures and 0% (0/4) of mock induced 
cultures. These data indicate that HSV-2 can establish a 
long-term (i.e., 30 days) quiescent state in ND-PC12 cell 
cultures Without the use of ACV, and virus reactivation 
results from forskolin induction. 
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What is claimed is: 
1. APC12 cell quiescently infected With a human herpes 
simplex 2 virus (HSV-2). 
2. A method of reactivating a quiescent virus from at least 
one quiescently-infected PC12 cell, comprising, introducing 
a reactivator to a cell of claim 1. 
3. A method for determining the ability of a test reagent 
to suppress virus reactivation from a quiescently-infected 
PC12 cell of claim 1, comprising: 
a) introducing a test reagent to said PC12 cell; and 
b) introducing to said PC12 cell a reactivator; and 
c) determining if reactivation has been suppressed. 
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4. A method for determining the ability of a test reagent 
to induce virus reactivation from a PC12 cell of claim 1, 
comprising: 
a) introducing a test reagent to said PC12 cell; and 
b) determining if reactivation has been induced. 
5. Amethod for eliciting phenotypic change in a PC12 cell 
of claim 1, introducing a reactivator to said PC12 cell, and 
eliciting a phenotypic change in said PC12 cell. 
6. The method of claim 5 Wherein said phenotypic change 
is selected from the group consisting of synthesis of myelin, 
synthesis of neurotransmitter, cell death, and viral shedding. 
7. A method to identify nucleic acid molecules and/or 
proteins involved in virus reactivation, comprising: 
a) reactivating a PC12 cell of claim 1 With a reactivator; 
and 
b) identifying nucleic acid molecules and/or proteins 
Which are uniquely expressed during reactivation. 
8. A method to identify the origins of DNA replication 
important to virus reactivation, comprising: 
a) reactivating a PC12 cell of claim 1 With a reactivator; 
and 
b) identifying the origins of replication Which are 
uniquely associated With reactivation. 
9. A method to screen a quiescent virus relative ability to 
be reactivated, comprising: 
a) introducing a reactivator to a PC12 cell of claim 1; and 
b) determining the relative magnitude of reactivation. 
10. A method to determine a reagent’s ability to inhibit 
establishment of a quiescent viral infection, comprising: 
a) introducing an HSV-2 virus to differentiated and viable 
PC12 cells in a serum-free, test reagent-containing 
medium; 
b) replenishing the medium after introducing the virus to 
maintain acceptable cell viability; and 
c) determining if reagent inhibited establishment of qui 
escence. 
11. A method of establishing quiescently-infected PC12 
cells, comprising: 
a) introducing a HSV-2 virus to neurally-differentiated 
and viable PC12 cells in a serum-free medium, said 
differentiated PC12 cells being in a container; and 
b) incubating said container With an antiviral reagent for 
a time necessary to accomplish quiescence of viral 
activity; and 
c) removing said antiviral agent from said container. 
12. The method of claim 11, Wherein the antiviral reagent 
is selected from the group consisting of acycloguanosine 
(acyclovir), Zidovudine (AZT), lamivudine (3TC), indinavir 
(IDV), ganciclovir, famciclovir, foscarnet, idoxyuridine, 
phosphoacetic acid, 5-?uorouracil, and analogs thereof. 
13. The method of claim 12, Wherein said container is 
incubated With acycloguanosine for approximately ?ve (5) 
to tWelve (12) days. 
14. The method of claim 13, Wherein said container is 
incubated at a temperature less than 40 degrees Celsius (40° 
C.). 
15. The method of claim 11, Wherein said serum-free 
medium alloWs for constant cell density and imparts neural 
characteristics to said cells. 
16. A method of establishing quiescently-infected PC12 
cells, comprising: 
a) introducing an HSV-2 virus to neurally-differentiated 
and viable PC12 cells in a serum-free medium; and 
b) replenishing the serum-free medium after introducing 
the virus to maintain acceptable cell viability. 
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17. A method of claim 16 wherein the medium is replen 
ished daily for 3 days and thereafter every tWo (2) to three 
(3) days until experimentation. 
18. A method to identify nucleic acid molecules and/or 
proteins involved in establishing virus quiescence, compris 
ing: 
a) establishing quiescence according to claims 11 or 16; 
and 
b) identifying nucleic acid molecules and/or proteins 
Which are uniquely expressed during establishment of 
quiescence. 
19. A method to identify the origins of DNA replication 
important to establishing virus quiescence, comprising: 
a) establishing quiescence according to claims 11 or 16; 
and 
b) identifying the origins of replication Which are 
uniquely associated With establishing quiescence. 
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20. A method to identify nucleic acid molecules and/or 
proteins involved in maintaining virus quiescence, compris 
mg: 
a) establishing quiescence according to claims 11 or 16; 
and 
b) identifying nucleic acid molecules and/or proteins 
Which are uniquely expressed during maintenance of 
quiescence. 
21. A method to identify the origins of DNA replication 
important to maintaining virus quiescence, comprising: 
a) establishing quiescence according to claims 11 or 16; 
and 
b) identifying the origins of replication Which are 
uniquely associated With maintaining quiescence. 
22. A method of claim 21 Wherein the medium is replen 
ished daily for 3 days and thereafter every tWo (2) to three 
(3) days until experimentation. 
* * * * * 
